M&A Deal Summary |
|
---|---|
Date | 2015-03-09 |
Target | MaSTherCell SA |
Sector | Life Science |
Buyer(s) |
Great Point Partners
Orgenesis |
Deal Type | Add-on Acquisition |
Deal Value | 25M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 2003 |
PE ASSETS | 1.7B USD |
Size | Large |
Type | Sector Focused |
Great Point Partners is a private investment firm focused on investing in private and public healthcare companies. Great Point's private equity practice invests $10 to $100 million of growth capital in private, growing companies. Specific areas of interest within the healthcare sector includes biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and worker compensation companies. Great Point Partners was formed in 2003 and is based in Greenwich, Connecticut.
DEAL STATS | # |
---|---|
Overall | 16 of 35 |
Sector (Life Science) | 6 of 14 |
Type (Add-on Acquisition) | 1 of 1 |
Country (Belgium) | 1 of 1 |
Year (2015) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-12-12 |
Connecture
Brookfield, Wisconsin, United States Connecture is a web-based consumer shopping, enrollment and retention platform for health insurance distribution. Connecture offers a personalized health insurance shopping experience that recommends the best fit insurance plan based on an individual’s preferences, health status, preferred providers, medications and expected out-of-pocket costs. Connecture’s customers are health insurance marketplace operators such as health plans, brokers and exchange operators, who must distribute health insurance in a cost-effective manner to a growing number of insured consumers. Connecture’s solutions automate key functions in the health insurance distribution process, allowing its customers to price and present plan options accurately to consumers and efficiently enroll, renew and manage plan members. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-08-24 |
Cytovance Biologics
Oklahoma City, Oklahoma, United States Cytovance is a contract manufacturing organization of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products. Cytovance supports its customers from clinical development to commercial launch in domestic and international markets. |
Sell | $206M |
Category | Company |
---|---|
Founded | 2008 |
Sector | Life Science |
Employees | 146 |
Revenue | 1M USD (2023) |
Orgenesis is a pre-clinical cell therapy and regenerative medicine company that is committed to curing Type 1 Diabetes. Orgenesis was founded in 2008 and is based in Germantown, Maryland.
DEAL STATS | # |
---|---|
Overall | 1 of 3 |
Sector (Life Science) | 1 of 3 |
Type (Add-on Acquisition) | 1 of 3 |
Country (Belgium) | 1 of 1 |
Year (2015) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-02-03 |
MaSTherCell SA
Gosselies, Belgium MaSTherCell SA (Manufacturing Synergies for Therapeutic Cells) is a technology-driven, customer-oriented Contract Development and Manufacturing Organization (CDMO) specialized in cell therapy development for advanced medicinal products. MaSTherCell was established in 2011 and is based in Gosselies, Belgium. |
Sell | $315M |